Dekabank Deutsche Girozentrale Reduces $298K in Arvinas, Inc. ($ARVN)
Key Points
- Dekabank Deutsche Girozentrale changed its Arvinas, Inc. ($ARVN) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ARVN is Buy and an average price target of $14.80.
- $ARVN last traded around $7.09.
Dekabank Deutsche Girozentrale reduced its position in Arvinas, Inc. ($ARVN), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Arvinas, Inc. after selling 42,000 shares during the quarter.
Arvinas, Inc. ($ARVN) Stock
Arvinas, Inc. Earnings
Analysts Set New Price Targets
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.